Antiretroviral Therapy Reduces Liver Decompensation Risk in HIV/HCV Coinfected Patients

HIV positive people with hepatitis C coinfection who start combination antiretroviral therapy (ART) are less likely to develop decompensated liver disease, or liver failure, according to a study published in the March 1, 2014, edition of Clinical Infectious Diseases. These findings offer further support for early ART initiation for people with viral hepatitis.

Read more:

AASLD 2013: Faldaprevir + Interferon/Ribavirin Leads to Early Sustained Response for HIV/HCV Coinfected

The HCV protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV positive people coinfected with genotype 1 hepatitis C in the STARTVerso4 trial, according to a poster presented at the 64th AASLD Liver Meeting last week in Washington, DC.

Read more:

Highlights from 2013 ICAAC, IDWeek, and EACS Meetings

Latest Positive Pulse Newsletter

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.

Read more:

AASLD 2013: Sofosbuvir + Ribavirin Produces Sustained Response in 76% of GT 1 HIV/HCV Coinfected Patients

An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured three-quarters of previously untreated HIV positive people coinfected with hepatitis C virus (HCV) genotype 1, while 12 weeks of treatment cured 88% and 67% of those with genotypes 2 or 3, according to findings from the Phase 3 PHOTON-1 study presented this week at the 64th AASLD Liver Meeting in Washington, DC.

Read more:

Antiretrovirals Reduce Liver Decompensation in HIV/HCV Coinfected

Starting antiretroviral therapy (ART) reduces the likelihood that HIV positive people coinfected with hepatitis C virus (HCV) will develop decompensated liver disease, according to a report published in the November 27, 2013, advance edition of Clinical Infectious Diseases.

Read more:

AASLD 2013: High Response Rates with Telaprevir Triple Therapy for HIV+ Men with Acute Hepatitis C

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and improves sustained response rates for HIV positive men with acute hepatitis C virus (HCV) infection, according to a presentation yesterday at the at the 64thAASLD Liver Meeting in Washington, DC.

Read more:

HIVandHepatitis.com Complete 2013 Conference Coverage

HIVandHepatitis.com 2013 conference and meeting coverage.

Full conference listing

12/30/13

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

Read more: